Login
Harmony Biosciences Holdings Inc logo

Harmony Biosciences Holdings Inc

harmonybiosciences.com

Harmony Biosciences Holdings Inc (NASDAQ: HRMY) is a pharmaceutical company that develops and commercializes treatments for patients living with rare and other neurological diseases. The company generates revenue through prescription drug sales, with its commercial products sold to patients via the U.S. healthcare system. The filing confirms HRMY is listed on the Nasdaq Global Market. The provided 10-K excerpts (filed 2026-02-24, accession 000110465926018859) do not contain sufficient detail to specify revenue figures, product names, market share, competitive positioning, founding year, CEO tenure, customer concentration, or geographic breakdown beyond a U.S. commercial presence implied by the filing structure. Only facts directly supported by the excerpts are included here; additional detail will require full 10-K body text.

Products & Services

The filing excerpts do not name specific products or brands.

Revenue Model

The filing excerpts do not provide sufficient detail to describe the revenue model with specific figures or product-level breakdown.

Customers & Markets

The filing excerpts reference neurological disease patients and industry markets but do not provide specific customer counts, concentration data, or end-market revenue splits.

Geographic Exposure

The filing excerpts do not provide a geographic revenue breakdown.

Financial Snapshot

Revenue
TTM
$899.1M
Gross Margin
TTM
76.82%
Net Income
TTM
$145.6M
Current Assets
2026 Q1
Current Liabilities
2026 Q1
Current Ratio
2026 Q1
358.34%
Total Assets
2026 Q1
Total Liabilities
2026 Q1
Book Value
2026 Q1
910.3M
Cash
2026 Q1
P/E
TTM
14.65
Free Cash Flow
TTM
$322.5M

Stock Price

Loading...
Market Cap: $2.1328 Billion

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support